drugset / Trial / NCT04420754
Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and tolerability and determine the recommended Phase 2 dose of AIC100 Chimeric Antigen Receptor (CAR) T cells in patients with relapsed/refractory poorly differentiated thyroid cancer and anaplastic thyroid cancer, including newly diagnosed.
Timeline
- Start
- 2020-09-28
- Primary completion
- 2026-08-04
- Completion
- 2030-08-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AIC100 | Cell therapy | 1e+06 cells | — |
| Subject | AIC100 | Cell therapy | 1e+07 cells | — |
| Subject | AIC100 | Cell therapy | 1e+08 cells | — |
| Subject | AIC100 | Cell therapy | 2.5e+08 cells | — |
| Subject | AIC100 | Cell therapy | 5e+08 cells | — |
| Subject | AIC100 | Cell therapy | 7.5e+08 cells | — |
| Subject | AIC100 | Cell therapy | 1e+09 cells | — |